AGMB - AgomAb Therapeutics N.V. American Depositary Shares Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

AGMB

AGOMAB THERAPEUTICS N.V. AMERICAN DEPOSITARY SHARES

NASDAQ

$12.17

▲ UP 0.75% (0.09)

KEY STATISTICS

Market Cap$599.35 M

52w High$17.82

52w Low$8.75

Dividend Yield—

Frequency—

P/E-0.26

Volume250.62K

Shares Out.49.25M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Tim Knotnerus

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 6, 2026

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$35.00

Target Low$35.00

Target Median$35.00

Target Consensus$35.00

UPCOMING EARNINGS

DateMar 3, 2027

DayWednesday

Rev. Est.—

MAR

WED

PRICE

$12.17 ▲ UP 0.75% (+$0.09)

About AgomAb Therapeutics N.V. American Depositary Shares

https://agomab.com ↗

AgomAb Therapeutics NV is a clinical-stage biopharma developing novel therapies for immunology and fibrotic diseases, with pipeline products in Phase 1 and 2 trials targeting Crohn's disease, pulmonary fibrosis, and regenerative medicine.

INDUSTRY

Biotechnology

A PRODUCT AGOMAB THERAPEUTICS N.V. AMERICAN DEPOSITARY SHARES IS KNOWN FOR

Ontunisertib (AGMB-129)

Ontunisertib, AgomAb Therapeutics' lead Phase 2a oral, gastrointestinal-restricted small molecule, is developed to treat Fibrostenosing Crohn's Disease, a severe complication with no approved therapies.